Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 48 | 2025 | 483 | 10.750 |
Why?
|
| Veterans | 48 | 2025 | 450 | 10.520 |
Why?
|
| Mental Disorders | 37 | 2025 | 567 | 9.670 |
Why?
|
| Criminals | 10 | 2024 | 42 | 4.300 |
Why?
|
| Opioid-Related Disorders | 23 | 2025 | 302 | 4.150 |
Why?
|
| Recidivism | 8 | 2025 | 20 | 3.860 |
Why?
|
| Cocaine-Related Disorders | 19 | 2017 | 51 | 3.330 |
Why?
|
| Mental Health Services | 16 | 2022 | 208 | 2.660 |
Why?
|
| Residential Treatment | 7 | 2025 | 18 | 2.300 |
Why?
|
| United States Department of Veterans Affairs | 28 | 2025 | 342 | 2.180 |
Why?
|
| Social Stigma | 4 | 2017 | 43 | 2.030 |
Why?
|
| Adult | 69 | 2025 | 10255 | 1.950 |
Why?
|
| Housing | 9 | 2024 | 52 | 1.920 |
Why?
|
| Criminal Law | 8 | 2025 | 57 | 1.910 |
Why?
|
| Humans | 126 | 2025 | 40217 | 1.900 |
Why?
|
| Mental Health | 13 | 2023 | 259 | 1.750 |
Why?
|
| United States | 40 | 2025 | 4886 | 1.690 |
Why?
|
| Schizophrenia | 13 | 2009 | 189 | 1.660 |
Why?
|
| Male | 68 | 2025 | 18271 | 1.590 |
Why?
|
| Cocaine | 15 | 2017 | 64 | 1.590 |
Why?
|
| Behavior, Addictive | 6 | 2016 | 61 | 1.520 |
Why?
|
| Female | 60 | 2025 | 20392 | 1.350 |
Why?
|
| Antipsychotic Agents | 11 | 2009 | 243 | 1.330 |
Why?
|
| Pilot Projects | 15 | 2024 | 680 | 1.330 |
Why?
|
| Substance Withdrawal Syndrome | 13 | 2005 | 92 | 1.310 |
Why?
|
| Coercion | 2 | 2022 | 44 | 1.290 |
Why?
|
| Middle Aged | 47 | 2025 | 10090 | 1.260 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 11 | 2024 | 68 | 1.180 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 306 | 1.170 |
Why?
|
| Community Mental Health Services | 3 | 2019 | 57 | 1.160 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 57 | 1.150 |
Why?
|
| Behavior Therapy | 3 | 2025 | 132 | 1.080 |
Why?
|
| Peer Group | 6 | 2020 | 76 | 1.080 |
Why?
|
| Program Evaluation | 3 | 2019 | 355 | 1.070 |
Why?
|
| Morals | 5 | 2022 | 13 | 1.030 |
Why?
|
| Mentoring | 2 | 2022 | 35 | 0.950 |
Why?
|
| Risperidone | 6 | 2006 | 22 | 0.890 |
Why?
|
| Opiate Substitution Treatment | 8 | 2024 | 126 | 0.870 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 243 | 0.850 |
Why?
|
| Chronic Pain | 1 | 2025 | 82 | 0.850 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 300 | 0.850 |
Why?
|
| Cues | 9 | 2017 | 55 | 0.840 |
Why?
|
| Comorbidity | 10 | 2025 | 717 | 0.830 |
Why?
|
| Case Management | 3 | 2020 | 42 | 0.750 |
Why?
|
| Benzodiazepines | 4 | 2018 | 77 | 0.720 |
Why?
|
| Prisons | 3 | 2019 | 61 | 0.700 |
Why?
|
| Drug Overdose | 2 | 2021 | 104 | 0.680 |
Why?
|
| Schizophrenic Psychology | 5 | 2009 | 48 | 0.670 |
Why?
|
| Social Support | 2 | 2019 | 274 | 0.660 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 90 | 0.660 |
Why?
|
| Tobacco Use Disorder | 6 | 2023 | 205 | 0.650 |
Why?
|
| Electroretinography | 9 | 2001 | 22 | 0.630 |
Why?
|
| Psychiatry | 1 | 2021 | 97 | 0.630 |
Why?
|
| Social Perception | 1 | 2019 | 26 | 0.620 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2019 | 11 | 0.620 |
Why?
|
| Treatment Outcome | 12 | 2019 | 2863 | 0.600 |
Why?
|
| Task Performance and Analysis | 2 | 2018 | 98 | 0.590 |
Why?
|
| Pharmacies | 1 | 2018 | 23 | 0.590 |
Why?
|
| Recovery of Function | 1 | 2019 | 134 | 0.590 |
Why?
|
| Educational Technology | 1 | 2018 | 9 | 0.570 |
Why?
|
| Craving | 5 | 2024 | 29 | 0.570 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 424 | 0.560 |
Why?
|
| Crime | 1 | 2018 | 30 | 0.560 |
Why?
|
| Buprenorphine | 5 | 2023 | 125 | 0.550 |
Why?
|
| Attitude to Health | 1 | 2019 | 213 | 0.550 |
Why?
|
| Massachusetts | 8 | 2022 | 1701 | 0.550 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 56 | 0.550 |
Why?
|
| Learning | 1 | 2018 | 124 | 0.520 |
Why?
|
| Informed Consent | 1 | 2017 | 111 | 0.520 |
Why?
|
| Cell Phone | 2 | 2014 | 31 | 0.510 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 84 | 0.510 |
Why?
|
| Algorithms | 3 | 2020 | 673 | 0.480 |
Why?
|
| Research | 1 | 2016 | 161 | 0.470 |
Why?
|
| Smoking Cessation | 5 | 2023 | 444 | 0.460 |
Why?
|
| Cognition Disorders | 3 | 2015 | 153 | 0.430 |
Why?
|
| Internet | 2 | 2014 | 338 | 0.430 |
Why?
|
| Neuropsychological Tests | 6 | 2003 | 231 | 0.430 |
Why?
|
| Primary Health Care | 2 | 2017 | 458 | 0.420 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 55 | 0.420 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 12 | 0.390 |
Why?
|
| Breathing Exercises | 1 | 2012 | 1 | 0.390 |
Why?
|
| Receptors, GABA-A | 1 | 2012 | 18 | 0.390 |
Why?
|
| Counseling | 5 | 2023 | 307 | 0.380 |
Why?
|
| Telemedicine | 2 | 2014 | 172 | 0.380 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 89 | 0.370 |
Why?
|
| Prisoners | 3 | 2019 | 103 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 260 | 0.350 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 353 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2009 | 293 | 0.350 |
Why?
|
| Alcoholism | 5 | 2021 | 219 | 0.340 |
Why?
|
| Psychotherapy, Brief | 1 | 2010 | 10 | 0.340 |
Why?
|
| Young Adult | 9 | 2024 | 2877 | 0.330 |
Why?
|
| Attitude of Health Personnel | 3 | 2024 | 375 | 0.330 |
Why?
|
| Stress, Psychological | 2 | 2024 | 344 | 0.300 |
Why?
|
| Depression | 2 | 2012 | 608 | 0.300 |
Why?
|
| Qualitative Research | 6 | 2024 | 421 | 0.290 |
Why?
|
| Cluster Analysis | 3 | 2019 | 197 | 0.290 |
Why?
|
| Neural Pathways | 1 | 2008 | 56 | 0.290 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 111 | 0.270 |
Why?
|
| Veterans Health | 5 | 2021 | 89 | 0.270 |
Why?
|
| Feasibility Studies | 3 | 2021 | 357 | 0.270 |
Why?
|
| Telephone | 3 | 2023 | 99 | 0.260 |
Why?
|
| Stereotyping | 2 | 2016 | 11 | 0.260 |
Why?
|
| Psychotherapy | 2 | 2017 | 59 | 0.260 |
Why?
|
| Social Discrimination | 2 | 2016 | 12 | 0.260 |
Why?
|
| Prejudice | 2 | 2016 | 44 | 0.260 |
Why?
|
| Monitoring, Ambulatory | 3 | 2015 | 50 | 0.250 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 45 | 0.250 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1668 | 0.230 |
Why?
|
| Substance Abuse Detection | 2 | 2015 | 39 | 0.230 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 68 | 0.230 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 51 | 0.230 |
Why?
|
| Health Status | 3 | 2020 | 297 | 0.220 |
Why?
|
| Acute Pain | 1 | 2024 | 11 | 0.220 |
Why?
|
| Serotonin Antagonists | 1 | 2004 | 7 | 0.220 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 10 | 0.220 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1367 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 320 | 0.210 |
Why?
|
| Smoking Prevention | 2 | 2015 | 139 | 0.210 |
Why?
|
| Aged | 12 | 2021 | 8182 | 0.210 |
Why?
|
| Retinal Cone Photoreceptor Cells | 4 | 1997 | 27 | 0.200 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2002 | 8 | 0.200 |
Why?
|
| World Health Organization | 1 | 2022 | 23 | 0.200 |
Why?
|
| Quality of Life | 3 | 2025 | 649 | 0.200 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 832 | 0.190 |
Why?
|
| Epidemics | 1 | 2022 | 17 | 0.190 |
Why?
|
| Health Personnel | 1 | 2024 | 236 | 0.190 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2017 | 10 | 0.190 |
Why?
|
| Outpatients | 2 | 2012 | 80 | 0.180 |
Why?
|
| Patient Compliance | 3 | 2013 | 222 | 0.170 |
Why?
|
| Health Planning | 1 | 2021 | 21 | 0.170 |
Why?
|
| Cannabidiol | 1 | 2020 | 5 | 0.170 |
Why?
|
| Social Problems | 1 | 2020 | 4 | 0.170 |
Why?
|
| Interview, Psychological | 2 | 2017 | 58 | 0.170 |
Why?
|
| Sex Factors | 3 | 2018 | 646 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 18 | 0.170 |
Why?
|
| Employment | 1 | 2021 | 97 | 0.170 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 38 | 0.160 |
Why?
|
| Public Housing | 1 | 2020 | 11 | 0.160 |
Why?
|
| Diabetes Mellitus | 3 | 2009 | 415 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 562 | 0.160 |
Why?
|
| Double-Blind Method | 5 | 2015 | 367 | 0.160 |
Why?
|
| Risk Factors | 3 | 2019 | 3141 | 0.160 |
Why?
|
| Methadone | 4 | 2023 | 78 | 0.160 |
Why?
|
| Health Plan Implementation | 2 | 2017 | 29 | 0.160 |
Why?
|
| Public Opinion | 1 | 2019 | 15 | 0.160 |
Why?
|
| Gambling | 2 | 2016 | 12 | 0.160 |
Why?
|
| Recurrence | 4 | 2015 | 364 | 0.150 |
Why?
|
| Pandemics | 1 | 2022 | 331 | 0.150 |
Why?
|
| Community Health Centers | 1 | 2019 | 57 | 0.150 |
Why?
|
| Boston | 1 | 2019 | 129 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2018 | 19 | 0.150 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 220 | 0.140 |
Why?
|
| Logistic Models | 3 | 2020 | 813 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 149 | 0.140 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 1998 | 21 | 0.140 |
Why?
|
| Adolescent | 7 | 2021 | 4034 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 289 | 0.140 |
Why?
|
| Program Development | 1 | 2019 | 157 | 0.140 |
Why?
|
| Needs Assessment | 2 | 2024 | 132 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 114 | 0.140 |
Why?
|
| Color Vision Defects | 1 | 1997 | 1 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2018 | 158 | 0.140 |
Why?
|
| Psychology, Clinical | 1 | 1997 | 6 | 0.140 |
Why?
|
| Dopamine | 3 | 2008 | 79 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 88 | 0.140 |
Why?
|
| Los Angeles | 1 | 2017 | 9 | 0.140 |
Why?
|
| Thinking | 1 | 2017 | 23 | 0.130 |
Why?
|
| Legislation, Medical | 1 | 2017 | 4 | 0.130 |
Why?
|
| Hospitalization | 2 | 2018 | 729 | 0.130 |
Why?
|
| Culture | 1 | 2017 | 58 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 1069 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 121 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 238 | 0.130 |
Why?
|
| Cooperative Behavior | 2 | 2024 | 158 | 0.130 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2015 | 15 | 0.120 |
Why?
|
| Social Justice | 1 | 2016 | 24 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2017 | 202 | 0.120 |
Why?
|
| Memantine | 1 | 2015 | 14 | 0.120 |
Why?
|
| Risk-Taking | 1 | 2016 | 101 | 0.120 |
Why?
|
| Naloxone | 1 | 2015 | 50 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2022 | 1958 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2013 | 1792 | 0.120 |
Why?
|
| Haloperidol | 2 | 2006 | 16 | 0.120 |
Why?
|
| Bipolar Disorder | 2 | 2009 | 185 | 0.110 |
Why?
|
| Child | 2 | 2020 | 2856 | 0.110 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 93 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 28 | 0.110 |
Why?
|
| Clinical Competence | 1 | 1997 | 448 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 3136 | 0.110 |
Why?
|
| Reminder Systems | 1 | 2014 | 57 | 0.110 |
Why?
|
| Cognition | 3 | 2023 | 345 | 0.110 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 109 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 395 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 274 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 419 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 1993 | 136 | 0.100 |
Why?
|
| Women's Health | 1 | 2015 | 320 | 0.100 |
Why?
|
| Motivation | 3 | 2015 | 205 | 0.100 |
Why?
|
| Biomarkers | 2 | 2024 | 945 | 0.100 |
Why?
|
| Patient Care Team | 2 | 2013 | 193 | 0.090 |
Why?
|
| Training Support | 1 | 2012 | 11 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2022 | 3138 | 0.090 |
Why?
|
| Machine Learning | 2 | 2024 | 124 | 0.090 |
Why?
|
| Genotype | 1 | 2012 | 444 | 0.090 |
Why?
|
| Educational Status | 1 | 2012 | 198 | 0.090 |
Why?
|
| Psychometrics | 3 | 2005 | 272 | 0.090 |
Why?
|
| Affect | 3 | 2017 | 84 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 70 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 99 | 0.080 |
Why?
|
| Pharmacists | 1 | 2009 | 81 | 0.070 |
Why?
|
| Time Factors | 3 | 2015 | 2422 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 150 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 120 | 0.070 |
Why?
|
| Color Perception | 2 | 1997 | 2 | 0.070 |
Why?
|
| Naltrexone | 2 | 2018 | 55 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2006 | 30 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2006 | 37 | 0.060 |
Why?
|
| New Jersey | 2 | 2004 | 17 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 358 | 0.060 |
Why?
|
| Smoking | 2 | 2016 | 584 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 1055 | 0.060 |
Why?
|
| Self Report | 2 | 2020 | 270 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 289 | 0.060 |
Why?
|
| Galvanic Skin Response | 2 | 2015 | 22 | 0.060 |
Why?
|
| HIV Infections | 1 | 2010 | 648 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2023 | 203 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 870 | 0.050 |
Why?
|
| Pirenzepine | 1 | 2003 | 4 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 450 | 0.050 |
Why?
|
| Mental Processes | 1 | 2023 | 13 | 0.050 |
Why?
|
| England | 1 | 2022 | 16 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 100 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 103 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2002 | 86 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2005 | 347 | 0.050 |
Why?
|
| Problem Solving | 1 | 2002 | 18 | 0.050 |
Why?
|
| Universities | 1 | 2022 | 111 | 0.050 |
Why?
|
| Reaction Time | 1 | 2002 | 92 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 215 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2002 | 91 | 0.040 |
Why?
|
| Attention | 1 | 2002 | 106 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 261 | 0.040 |
Why?
|
| Dronabinol | 1 | 2020 | 30 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 82 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 11 | 0.040 |
Why?
|
| Social Welfare | 1 | 2020 | 11 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 46 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 870 | 0.040 |
Why?
|
| Nicotine | 1 | 2020 | 102 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 370 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 47 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 463 | 0.040 |
Why?
|
| Chlorpromazine | 1 | 1999 | 7 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 201 | 0.040 |
Why?
|
| Clozapine | 1 | 1999 | 27 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2002 | 1479 | 0.040 |
Why?
|
| Drive | 1 | 1997 | 1 | 0.040 |
Why?
|
| Eye Movement Measurements | 1 | 2017 | 18 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 308 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 38 | 0.030 |
Why?
|
| Color Perception Tests | 1 | 1997 | 1 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2017 | 39 | 0.030 |
Why?
|
| Psychological Theory | 1 | 1997 | 17 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 36 | 0.030 |
Why?
|
| Education, Graduate | 1 | 1997 | 12 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 66 | 0.030 |
Why?
|
| Retina | 1 | 1997 | 92 | 0.030 |
Why?
|
| Research Personnel | 1 | 1997 | 74 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 165 | 0.030 |
Why?
|
| Eye Movements | 1 | 2017 | 76 | 0.030 |
Why?
|
| Teaching | 1 | 1997 | 121 | 0.030 |
Why?
|
| Skin Temperature | 1 | 2015 | 10 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 246 | 0.030 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2010 | 66 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 548 | 0.030 |
Why?
|
| Medicare | 2 | 2009 | 370 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 127 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 53 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 268 | 0.030 |
Why?
|
| Body Temperature | 1 | 2015 | 33 | 0.030 |
Why?
|
| Wrist | 1 | 2015 | 32 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 600 | 0.030 |
Why?
|
| Mass Screening | 1 | 1996 | 409 | 0.030 |
Why?
|
| Primary Prevention | 1 | 1993 | 88 | 0.030 |
Why?
|
| Health Education | 1 | 1993 | 151 | 0.020 |
Why?
|
| Wireless Technology | 1 | 2012 | 17 | 0.020 |
Why?
|
| Vocational Guidance | 1 | 2012 | 17 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 200 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 223 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 52 | 0.020 |
Why?
|
| Drug Packaging | 1 | 2009 | 11 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 970 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 148 | 0.020 |
Why?
|
| Classification | 1 | 2007 | 5 | 0.020 |
Why?
|
| Population | 1 | 2007 | 13 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2005 | 47 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 112 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 89 | 0.010 |
Why?
|
| Benztropine | 1 | 2003 | 2 | 0.010 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2003 | 5 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 14 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 59 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 113 | 0.010 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1999 | 1 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1999 | 4 | 0.010 |
Why?
|
| Weight Gain | 1 | 1999 | 140 | 0.010 |
Why?
|
| Color | 1 | 1997 | 20 | 0.010 |
Why?
|
| Arousal | 1 | 1996 | 28 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 222 | 0.010 |
Why?
|
| Patient Admission | 1 | 1996 | 115 | 0.010 |
Why?
|
| Incidence | 1 | 1996 | 773 | 0.010 |
Why?
|